Provet Cloud vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cloud Veterinary Information Management System
Cloud-based veterinary information management system acquired by Nordhealth; Helsinki Finland; serves 3,000+ clinics across Europe, Australia, New Zealand, and North America;
About
Provet Cloud is a cloud-based veterinary information management system (VIMS) that provides veterinary practices with patient records, appointment scheduling, invoicing, pharmacy management, lab integration, and reporting in a browser-accessible platform, developed and headquartered in Helsinki, Finland and acquired by Nordhealth, the Nordic health technology group. Provet Cloud serves more than 3,000 veterinary clinics across Europe, Australia, New Zealand, and North America, making it one of the most internationally deployed cloud-native veterinary practice management platforms available.\n\nProvet Cloud's platform is designed for general veterinary practices, emergency clinics, and specialty hospitals, offering a clinical workflow that tracks patients from check-in through consultation, diagnostics, treatment, and discharge with integrated invoicing and payment collection. Lab integrations connect directly to in-house analyzers and external diagnostic labs, bringing results into the patient record automatically. The platform's multi-location and multi-user architecture supports corporate veterinary groups and franchise networks that need consolidated reporting across clinics while maintaining individual clinic workflows. APIs allow integration with third-party diagnostic, imaging, and practice growth tools.\n\nAs part of Nordhealth, Provet Cloud benefits from investment in development resources and synergies with Nordhealth's other healthcare technology platforms. Provet Cloud competes with ezyVet (owned by IDEXX), Digitail, Vetspire, and the legacy PIMS offerings from IDEXX and Henry Schein. Its strong presence in European and Australasian markets differentiates it from US-centric competitors, and its API-first architecture appeals to technology-forward practices and corporate groups building integrated technology stacks.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.